Rationale for using lenvatinib as an urgent initial therapy in thyroid cancer with remarkable laryngotracheal invasion.

Martinod E, Kuczma P, Trésallet C, Ghander C, Buffet C, Vicaut E

DOI: 10.1530/etj-25-0337
Published: 2025 Dec 1
Container: European thyroid journal
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1530/etj-25-0337,
  title = {Rationale for using lenvatinib as an urgent initial therapy in thyroid cancer with remarkable laryngotracheal invasion.},
  author = {Martinod E and Kuczma P and Trésallet C and Ghander C and Buffet C and Vicaut E},
  year = {2025},
  journal = {European thyroid journal},
  doi = {10.1530/etj-25-0337},
  url = {https://doi.org/10.1530/etj-25-0337}
}

RIS

TY  - JOUR
TI  - Rationale for using lenvatinib as an urgent initial therapy in thyroid cancer with remarkable laryngotracheal invasion.
AU  - Martinod E
AU  - Kuczma P
AU  - Trésallet C
AU  - Ghander C
AU  - Buffet C
AU  - Vicaut E
PY  - 2025
JO  - European thyroid journal
DO  - 10.1530/etj-25-0337
UR  - https://doi.org/10.1530/etj-25-0337
ER  -

APA

E, M., P, K., C, T., C, G., C, B., & E, V. (2025). Rationale for using lenvatinib as an urgent initial therapy in thyroid cancer with remarkable laryngotracheal invasion.. European thyroid journal. https://doi.org/10.1530/etj-25-0337

Source records

pubmed · retrieved 2026-09-26T09:14:14.087Z